IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Cochaud, Stéphanie ^a   Giustiniani, Jérôme ^b   Thomas, Clémence ^c   Laprevotte, Emilie ^a   Garbar, Christian ^b   Savoye, Aude Marie ^b   Curé, Hervé ^b   Mascaux, Corinne ^b   Alberici, Gilles ^c   Bonnefoy, Nathalie ^a   Eliaou, Jean François ^a,d   Bensussan, Armand ^a   Bastid, Jeremy ^c  

^a INSERM   (France)

^b INSTITUT JEAN GODINOT   (France)

^c OREGA Biotech   (France)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; ESTROGEN RECEPTOR; INTERLEUKIN 17; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TAXOID;

BIOPSY; BIOSYNTHESIS; BREAST NEOPLASMS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIOPSY; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERLEUKIN-17; LYMPHOCYTES, TUMOR-INFILTRATING; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; RECEPTORS, ESTROGEN; TAXOIDS;

EID: 84890212018     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03456     Document Type: Article

References (42)

1. Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436-444, doi:10.1038/nature07205 (2008).
2. Gaffen, S. L. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9, 556-567, doi:10.1038/nri2586 (2009).
3. Onishi, R. M. & Gaffen, S. L. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 129, 311-321, doi:10.1111/ j.1365-2567.2009.03240.x (2010).
4. Iwakura, Y., Ishigame, H., Saijo, S. & Nakae, S. Functional specialization of interleukin-17 family members. Immunity 34, 149-162, doi:10.1016/ j.immuni.2011.02.012 (2011).
5. Ji, Y. & Zhang, W. Th17 cells: positive or negative role in tumor? Cancer Immunol Immunother 59, 979-987, doi:10.1007/s00262-010-0849-6 (2010).
6. Zhu, X. et al. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 10, R95, doi:10.1186/bcr2195 (2008).
7. Jung, M. Y., Kim, S. H., Cho, D. & Kim, T. S. Analysis of the expression profiles of cytokines and cytokine-related genes during the progression of breast cancer growth in mice. Oncol Rep 22, 1141-1147 (2009).
8. Su, X. et al. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 184, 1630-1641, doi:10.4049/jimmunol. 0902813 (2010).
9. Benevides, L. et al. Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor. Eur J Immunol, doi:10.1002/eji.201242951 (2013).
10. Chen, W. C. et al. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histopathology, doi:10.1111/his.12156 (2013).
11. Nam, J. S. et al. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 68, 3915-3923, doi:10.1158/0008-5472.CAN-08-0206 (2008).
12. MacKeigan, J. P., Collins, T. S. & Ting, J. P. MEK inhibition enhances paclitaxelinduced tumor apoptosis. J Biol Chem 275, 38953-38956, doi:10.1074/ jbc.C000684200 (2000). (Pubitemid 32058904)
13. Favata, M. F. et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273, 18623-18632 (1998). (Pubitemid 28334795)
14. Chang, Y. et al. Th17-associated cytokines promote human airway smooth muscle cell proliferation. Faseb J 26, 5152-5160, doi:10.1096/fj.12-208033 (2012).
15. Acosta, J. J. et al. Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways. Mol Endocrinol 17, 2268-2282, doi:10.1210/me.2002-0422 (2003). (Pubitemid 37352537)
16. Gu, F. M. et al. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol Cancer 10, 150, doi:10.1186/ 1476-4598-10-150 (2011).
17. Li, Q. et al. IL-17 promoted metastasis of non-small-cell lung cancer cells. Immunol Lett 148, 144-150, doi:10.1016/j.imlet.2012.10.011 (2012).
18. Li, J. et al. Interleukin 17A promotes hepatocellular carcinoma metastasis via NFkB induced matrix metalloproteinases 2 and 9 expression. PLoS One 6, e21816, doi:10.1371/journal.pone.0021816 (2011).
19. Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14, 518-527, doi:10.1038/nm1764 (2008). (Pubitemid 351655218)
20. DeSelm, C. J. et al. IL-17 mediates estrogen-deficient osteoporosis in an Act1- dependent manner. J Cell Biochem 113, 2895-2902, doi:10.1002/jcb.24165 (2012).
21. Tyagi, A. M. et al. Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. PLoS One 7, e44552, doi:10.1371/journal.pone.0044552 (2012).
22. Lee, S. Y. et al. IL-17-mediated Bcl-2 expression regulates survival of fibroblastlike synoviocytes in rheumatoid arthritis through STAT3 activation. Arthritis Res Ther 15, R31, doi:10.1186/ar4179 (2013).
23. Olsson Akefeldt, S. et al. Chemoresistance of human monocyte-derived dendritic cells is regulated by IL-17A. PLoS One 8, e56865, doi:10.1371/ journal.pone.0056865 (2013).
24. Wang, L., Yi, T., Zhang, W., Pardoll, D. M. & Yu, H. IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res 70, 10112-10120, doi:10.1158/0008-5472.CAN-10-0775 (2010).
25. Wang, L. et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206, 1457-1464, doi:10.1084/jem.20090207 (2009).
26. Huang, H. et al. IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling. Cell Death Differ 16, 1332-1343, doi:10.1038/cdd.2009.74 (2009).
27. Hemdan,N. Y. Anti-cancer versus cancer-promoting effects of the interleukin-17- producing T helper cells. Immunol Lett 149, 123-133, doi:10.1016/ j.imlet.2012.11.002 (2013).
28. Maniati, E., Soper, R. &Hagemann, T. Up for Mischief? IL-17/Th17 in the tumour microenvironment. Oncogene 29, 5653-5662, doi:10.1038/onc.2010.367 (2010).
29. Numasaki, M. et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 101, 2620-2627, doi:10.1182/blood-2002-05-1461 (2003). (Pubitemid 36857622)
30. Numasaki, M. et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2- dependent angiogenesis. J Immunol 175, 6177-6189 (2005). (Pubitemid 41508106)
31. Wu, S. et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15, 1016-1022, doi:10.1038/nm.2015 (2009).
32. Muranski, P. et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112, 362-373, doi:10.1182/blood-2007-11-120998 (2008).
33. Hinrichs, C. S. et al. Type 17 CD81T cells display enhanced antitumor immunity. Blood 114, 596-599, doi:10.1182/blood-2009-02-203935 (2009).
34. Chae, W. J. et al. Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci U S A 107, 5540-5544, doi:10.1073/ pnas.0912675107 (2010).
35. Carmi, Y. et al. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol 186, 3462-3471, doi:10.4049/jimmunol. 1002901 (2011).
36. Zhang, Q. et al. Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Res 72, 2589-2599, doi:10.1158/0008- 5472.CAN-11-3795 (2012).
37. Das Roy, L. et al. Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. Breast Cancer Res 11, R56, doi:10.1186/bcr2345 (2009).
38. Novitskiy, S. V. et al. TGF-beta receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. Cancer Discov 1, 430-441, doi:10.1158/2159-8290.CD-11-0100 (2011).
39. Coury, F. et al. Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. NatMed 14, 81-87, doi:10.1038/nm1694 (2008).
40. Bagot, M. et al. Isolation of tumor-specific cytotoxic CD41and CD41CD8dim1 T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood 91, 4331-4341 (1998). (Pubitemid 28261998)
41. Miyagaki, T. et al. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma. Clin Cancer Res 17, 7529-7538, doi:10.1158/1078-0432. CCR-11-1192 (2011).
42. Mayer, C. et al. DNA repair capacity after gamma-irradiation and expression profiles of DNA repair genes in resting and proliferating human peripheral blood lymphocytes. DNA Repair (Amst) 1, 237-250 (2002). (Pubitemid 34465485)